Developing mRNA vaccines and therapeutics In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company. This acquisition further accelerates Sanofi’s efforts to develop transformative vaccines and therapies using mRNA technology. It adds a critical pillar to the company’s mRNA Center of Excellence, which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We …

144 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Precision Engineered Medicines to Silence Diseases Our 20-plus years of RNAi experience together with our validated mRNAi GOLDTM platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients …

77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com. Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, CAR-T, Systemic lupus erythematosus, Autoimmunity, Autoimmune Disease, and Lupus

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transcribing For Better Lives Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of innovative drugs for indications with unmet medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies, a polypeptide nanoparticle RNAi platform and GalNAc RNAi platform, GalAheadTM, Sirnaomics has established an enriched drug candidate pipeline. STP122G, which represents the first drug candidate utilizing the Group's GalAheadTM mxRNA technology, is currently in Phase I development. STP125G is the second siRNA therapeutics …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading the Next Frontier of Cell Therapy Sonoma Biotherapeutics is a South San Francisco and Seattle-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. Sonoma Bio has initiated two Phase 1 studies to evaluate the safety and proof-of-mechanism of the company’s lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis and hidradenitis suppurativa. …

129 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing cancer immunotherapy by targeting the unconventional Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors. Through our proprietary EnTiCE platform, Enara is developing novel bispecific T cell engagers against Dark Antigen targets that are highly prevalent and homogenously expressed across solid …

87 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Axonis Therapeutics is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University. The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potentially blockbuster drug space. Axonis’ lead development candidate, AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter …

128 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reimagining known biology to deliver high impact medicines Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Pharmaceuticals, Liver Disease, Life Sciences, BioPharmaceuticals, CML, Oncology, and HemOnc

343 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The leading experts in cancer cell capture and analysis from liquid biopsies ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE’s commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. …

277 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI

267 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology

Argonaute RNA Ltd. is developing safe and reliable methods of temporarily silencing target genes in different tissue cells. Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein. Argonaute RNA research projects build on existing intellectual property. We show how our proprietary modification of small interfering RNA (siRNA) allows safe and effective ways to silence specific gene expression. We use a novel method of stabilising the siRNA and thereby avoid a range of issues which have …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products, ProNephro AKITM and The NGAL TestTM, are based …

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting the root cause of neurodegeneration Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & …

73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability. Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections …

236 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

We develop Optimer® binders to enable innovation across the life science industry. Aptamer Group develops Optimer® binders to enable innovation in the life science industry. Get our newsletter: https://aptamergroup.com/newsletter Research and Development, Assay Development, Custom development, Drug development, Custom reagents, Agriculture testing, Aptamers, Biomarker discovery, Affinity ligands, Environmental testing, Affinity chromatography ligands, ADCs / AOCs, QC reagents, Diagnostic tools, and Targeted delivery

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

www.aukera-tx.com Aukera Therapeutics is a spin-off from the Biozentrum at the University of Basel, developing the first RAPTOR inhibitors for the treatment of mTORC1-related pathologies. We pair deep mTOR expertise with an AI-driven drug discovery engine built for complex and hard-to-drug targets. Our lead program focuses on rare neurological disorders such as Tuberous Sclerosis. Future applications of RAPTOR inhibitors include neurodegenerative, metabolic, and age-related diseases.

98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

Biotech specialized in the design of new medicine. Let's connect to know more about us ! At Aceso, we leverage our technology platform to explore new molecular pathways and develop strategic approaches aimed at redefining standards of care where existing therapies are insufficient. In the development of a new therapy for cystic fibrosis, Aceso is starting with ATC-101, its most advanced program designed to address the limitations of current treatments. Supported by robust proof-of-concept data and promising preclinical evidence, we are advancing toward IND-enabling studies, with entry into clinical trials as the next major milestone. With a science-driven roadmap and …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For …

633 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Cellectis is developing life-changing product candidates to target and eradicate cancer cells. Cellectis is a global, clinical-stage biopharmaceutical company. As pioneers and innovators in our field, we are driven by a single mission: to develop breakthrough treatments for patients with unmet medical needs. With 26 years of expertise, we operate a best-in-class genome editing platform focused on immuno-oncology and gene therapy. By leveraging our proprietary gene-editing technologies, we engineer allogeneic CAR-T cells designed to recognize and eliminate cancer cells. Currently, our two lead clinical programs are evaluating therapies for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). As a …

173 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

171 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing cardiovascular care through science, innovation, and a commitment to better patient outcomes worldwide Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally through a syndicate of reputable and well-established partners with significant …

190 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

443 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AI-driven Personalized Medicine for Cancer Care ImpriMed, founded in 2017 in Silicon Valley, is a leading precision medicine startup revolutionizing cancer treatment with artificial intelligence. The company’s pioneering drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, the company’s technology has been deployed across more than 40 U.S. states, and 22,000+ canine and feline blood cancer tests have been performed as of 2026. ImpriMed is now poised to extend its groundbreaking AI-driven approach to human healthcare, redefining the future of oncology treatment with personalized, effective solutions. For additional …

191 similar entities Type: Startup Activities: pettech deeptech biotech Technologies: A.I.

Dream ahead. RIBOPRO is an innovative service provider, producing high-quality, high-performance RNA products, which are used as powerful research tools and therapeutics. RiboPro offers both off-the-shelf and custom RNA products at competitive rates and turn-around times, effectively removing all barriers to successful use of RNA in the research and development of our customers. We have more than a decade of experience satisfying the RNA-related needs of almost 300 customers worldwide and thus we are confident that we can help you get your next project off to a good start. Let us worry about the quality and performance of your RNA, …

59 similar entities Type: Startup Activities: manufacturing deeptech Technologies: Synthetic Biology

Bone targeted delivery concept Atlanthera is a drug discovery company focused on bone diseases and bone cancer treatments Our vision: Be the leader in bone-targeted drug delivery to cure bone cancer and metastases Atlanthera can rely on a very high-qualified Team and a worldwide-known experts network Our concept: Bone-targeted delivery of anti-cancer drug www.atlanthera.com Watch our concept in video > https://youtu.be/m3BBWguO6hs Durg discovery, Bone-targeted drug delivery, Bone cancer, and Bone metastases

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

284 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of …

109 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more AlzeCure Pharma is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such …

204 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A new class of cancer therapies using RNA-guided nucleases for specific cell depletion Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and RNA, but only if there is a highly specific match between the guide RNA and an intracellular RNA sequence, ensuring that only the targeted cells are affected, leaving healthy cells unharmed. Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), Akribion is exploring additional applications in oncology, autoimmune diseases, fibrosis, and infectious diseases. The flexibility and broad potential of Akribion's …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Translating genetic discoveries into safe and effective treatments. Arctic Therapeutics is a clinical-stage biopharmaceutical company on a mission to treat and even prevent some of the world’s most pressing diseases by utilizing genetic sequencing to analyze and map the genetic causes of diseases at a granular level, applying our findings to develop effective treatments. Our company was founded by Dr. Hakon Hakonarson in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), which he launched in 2006 and established it as the largest pediatric biobank and genomic database in the world. We maintain close research relationships with …

368 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Captor Therapeutics is a publicly-listed (WSE:CTX) innovative drug discovery and development company focused on targeting the undruggable proteome using targeted protein degradation. Our mission is to transform lives of patients suffering from cancer, autoimmunity and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to create new drug candidates with the potential to ease patients' burden and cure conditions that so far have only been poorly treatable. Captor Therapeutics S.A. implements projects co-financed by the European Union. All information about the projects is available at: https://captortherapeutics.com/grant-projects. drug development, biotechnology, and protein degradation

734 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing allogeneic TCR-NK therapies for solid tumors Zelluna is pioneering allogeneic ‘off-the-shelf’ T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of solid cancers. The company’s platform combines the innate killing power of NK cells with precise solid tumour targeting of TCRs, designed to address the limitations of current cell therapies in solid tumours. The company’s lead candidate, ZI-MA4-1, is the worlds-first MAGE-A4 targeting TCR-NK therapy expected to enter clinical trials in 2026 For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors

293 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our vision is to harness the power of the immune system to develop novel therapies against cancer & infectious diseases. Biopharmaceutical New Technologies (BioNTech) is a global biotechnology company aspiring to translate science into survival by developing new immunotherapies utilizing the full potential of the immune system to fight cancer and infectious diseases. BioNTech is headquartered in Mainz, Germany, and operates globally with almost 7.000 pioneers. Our work is powered by one mission: Improving the health of people worldwide. We believe that scientific rigor and passion are the driving forces that are essential for innovative progress. BioNTech was founded in …

270 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the broad potential of RNA medicines to transform human health We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, …

114 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Eurofins Discovery offers you a complete, single-source solution for drug discovery products and services. Eurofins Discovery has supported Drug Discovery research for >40 years. Our partners inspire us to innovate in the pursuit of life-changing cures. We provide our experience, depth, and breadth in the form of innovative testing services and product tools that support researchers as they accelerate the discovery and development of candidate molecules. Our global team of dedicated scientists, information analysts, and client support professionals make this mission possible. Our focus drives us to continually expand our portfolio of testing methods, tools, and services to enable real, …

382 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com. Nuclear Medicine & Nuclear Industry, Biotechnology, Pharmaceutical, …

220 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us at @agenus_bio. Our Community Guidelines are available at our website and at: https://agenusbio.com/community-guidelines/ Immuno-oncology, Cancer Vaccines, Checkpoint Inhibitors and Modulators, Immunotherapy, Cell therapy, Antibodies, and GMP Manufacturing

171 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development

205 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We power your science Sartorius Polyplus is a leading upstream solutions provider for advanced biological and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help customers (or the industry) optimize process economics while meeting strict scientific and regulatory standards. ​ ​ We wanted to share that we will not be actively posting or engaging on this LinkedIn account. …

114 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing Next Generation mRNA Vaccines pHion Therapeutics is a UK based biotech delivering ground-breaking nucleic acid vaccines and therapeutics. The proprietary RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo (RNA and DNA), irrespective of size, into nanoparticles. These nanoparticles are highly efficient at cellular entry with 100% release from the endosomes. When used in vaccines, the RALA platform can deliver multiple anionic molecules, such as mRNA, in a stealth-like way by evading detection. This generates both a potent antigen-specific CD8+ T-cell response that is ideal for therapeutic vaccines, and a …

128 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Altamira is developing peptide-based nanoparticles (xPhoreTM) for delivery of nucleic acids to extrahepatic tissues. Altamira Therapeutics is developing and supplying peptide-based nanoparticles (xPhoreTM) for delivery of nucleic acids to extrahepatic tissues. This versatile technology is suited for delivering different nucleic acid modalities: OligoPhoreTM for small RNAs (siRNA/ASO), SemaPhoreTM for mRNA, CycloPhoreTM for circRNA and GenePhoreTM for DNA. xPhoreTM is licensed to pharma and biotech companies for use with their proprietary nucleic acid molecules. The Company currently has two proprietary siRNA programs using OligoPhoreTM in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for …

63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Mastering Mast Cells Allegria Therapeutics was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that directly and selectively modulate mast cells, Allegria aims to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases. For more information, please visit https://allegriatx.com/. Mast Cell-Targeted Therapeutics, Allergy, and Inflammatory Disease

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are a specialist respiratory biotech company focused on severe viral lung infections Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www.synairgen.com.

73 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Exosome-based therapeutics Exogenus Therapeutics is an innovative biotech start-up dedicated to early stage development of therapeutic tools. Using an exosome-based platform technology, Exogenus is developing biologic products for diseases with high unmet needs, such as inflammatory and autoimmune diseases. Driven by the urgency imposed by the COVID-19 pandemic, the company is currently developing solutions for the treatment of severe lung inflammation, a condition with limited treatment options and a common cause of death following SARS‐CoV‐2 infection. Contact us at team@exogenus-t.com Biotechnology, Regenerative Medicine, Stem cells, exosomes, cell biology, and therapies

293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Supercharging Immunotherapy At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV …

137 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing our proprietary AxiomerTM RNA-editing platform technology Changing lives is what drives us at ProQR Therapeutics. We are advancing our proprietary AxiomerTM RNA-editing platform technology. Our highly energetic team strives to combine innovative technologies and entrepreneurism to make a meaningful impact on the lives of individuals and the people around them. If you are up to this challenge and like to be part of our team, check out our website for vacancies: http://www.proqr.com/careers/ RNA therapeutics, Drug development, Rare Diseases, Genetic Diseases, Orphan drugs, Pharmaceuticals, and RNA editing

174 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. Together with our research collaborations with premiere institutions …

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Fueled by Connections to Transform Rare DiseasesTM Agios is a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with rare disease communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. Rooted in hematology, we combine deep biological expertise with real-world insights to advance a growing pipeline of medicines that reflect patients’ priorities. Our inclusive, collaborative culture sparks bold thinking and strengthens our connections – with each other and with the people we serve. Review our social media guidelines: https://www.agios.com/community-guidelines/ Biopharmaceuticals, Cellular Metabolism, and Rare …

312 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Biotech company focusing on the discovery and development of novel targeted medicines to treat cancer and fibrosis Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of scientists are based at our labs at Alderley Park, Cheshire, the UK’s largest single site life science campus. The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience. Redx's lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for …

266 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ikena merged with ImageneBio on in July 2025. Please visit https://inmagenebio.com/ for more information. Ikena merged with ImageneBio in July 2025. Please visit https://inmagenebio.com/ for more information. Targeted Oncology, cancer therapeutics development, small molecule drug design, cancer biology, and translational science and biomarkers

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing novel circular RNA and immunotherapy medicines. Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is …

94 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com.

281 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging genetics to treat neurological diseases Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs …

159 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Any Gene to Any Cell Viral Vector Services from Vector Engineering and Manufacturing to Cell and Gene Therapy Development Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. Whether you need small scale viral production or full scale viral vector optimization and manufacture, our expert team has you covered. For additional information, please visit www.sirion-biotech.com. AAV, Lentivirus, Custom viral vectors, Virus production, AAV engineering for gene therapy, LentiBOOST, and Gene delivery

107 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Leading the way in targeted protein degradation therapeutics Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- …

65 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Novalix is a premier drug discovery CRO Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit www.novalix.com Target based drug discovery, NMR, SPR, Epigenetic targets, Nuclear receptors, Protein-ligand co-crystal structures by XRD, Native mass spectrometry, FBDD, Organic Chemistry, cryo-electron microscopy, Chemical development, Medicinal chemistry, Structural Biology, in vitro pharmacology, DNA-encoded libraries, Flow chemistry, Chemical process research, DMPK, and ADME

515 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneer of Click-to-Release chemistry; designing more effective and safer systemic therapies Tagworks Pharmaceuticals is a precision oncology company using our proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Our lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. We are developing a pipeline of novel cancer treatments leveraging our Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted …

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovation in Marine-Derived Oncology Therapies Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other …

119 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing Innovative Cell Therapies Against Cancer Celyad Oncology is a biotechnology company focused on the discovery and development of tecnhlologies and platform for chimeric antigen receptor T cell (CAR T) therapies. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Immuno-Oncology, Cancer, Immnotherapy, shRNA multiplex, and CAR T-cells

149 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology